The global pruritus therapeutics market size accounted for USD 11.25 billion in 2024, grew to USD 11.74 billion in 2025 and is projected to surpass around USD 17.26 billion by 2034, representing a healthy CAGR of 4.37% between 2024 and 2034. The North America pruritus therapeutics market size is worth around USD 4.61 billion in 2024 and is expected to grow at a fastest CAGR of 4.38% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pruritus Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pruritus Therapeutics Market, by Disease Type, 2024-2034
8.1.1 Atopic Dermatitis
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Allergic Contact Dermatitis
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Urticaria
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Pruritus Therapeutics Market, by Product, 2024-2034
9.1.1. Corticosteroids
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Antihistamines
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Local Anesthetics
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Counterirritants
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Immunosuppressant
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Calcineurin Inhibitors
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2021-2034)
10.1. Pruritus Therapeutics Market, by Distribution Channel, 2024-2034
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Drug Stores & Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Online Providers
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Product (2021-2034)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1. Amgen, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Cara Therapeutics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Abbvie, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Astellas Pharma
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bristol-Myers Squibb
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Actavis Plc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Mylan NV
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. GlaxoSmithKline, Plc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Pfizer Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample